Prostate Advances News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The phase 3 PACE-B trial demonstrated that stereotactic body radiation therapy is noninferior to conventional radiation therapy for low- and favorable-intermediate-risk prostate cancer with respect to biochemical clinical failure. Stereotactic body radiation therapy is noninferior to conventional external beam radiation therapy for low- and favorable-intermediate-risk prostate cancer.

A clinical trial from the United Kingdom suggests that doctors can safely reduce radiotherapy exposure time for prostate cancer treatment by administering higher radiation doses.

People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.

Phase III trial finds fewer, higher doses cut treatment time while maintaining high rates of cure

Men could receive their entire course of treatment in five doses, according to research.